Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor ...

US-based Iambic Therapeutics has concluded the dose escalation phase in its multi-centre Phase I/Ib trial of a ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Day One Biopharmaceuticals' Q1'25 sales grew modestly, but Q2 2025 earnings could spark movement. Read why I currently rate ...

The rate of doctors’ visits has a direct impact on diagnostic imaging volumes and thus is relevant for stocks such as Sonic ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...

Increased consumption of olive oil may reduce the risk for specific subtypes of breast cancer, according to results of a ...

The 2025 ASCO Annual Meeting data presentation can be accessed on the Publications section of the Mersana website at www.mersana.com.

In an interim analysis from the DESTINY-Breast09 study, the combination of the antibody-drug conjugate trastuzumab deruxtecan ...